The use of plerixafor in harvesting autologous stem cells in the pediatric setting.
The mobilization of stem cells using the standard approach, chemotherapy and G-CSF, may not be successful in all cases heavily pretreated. Plerixafor (AMD3100) has emerged as a viable option in attempts to mobilize stem cells among these patients. The use of plerixafor in the adult setting has been established, but data on pediatric use is scarce. We report on the use of plerixafor in eight pediatric cases either as add-on to chemotherapy plus G-CSF or in remobilization.
Division of Pediatric Hematology-Oncology, University of Tampere, Tampere, Finland. kim.vettenranta@pshp.fi
Kim
K
Vettenranta
Merja
M
Möttönen
Pekka
P
Riikonen
D000293:Adolescent; D000328:Adult; D002469:Cell Separation / Q000295:instrumentation* / Q000379:methods; D002648:Child; D002675:Child, Preschool; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D014182:Transplantation, Autologous